Sickle Cell Patients Miss Lifesaving Treatment Despite Access

Sickle cell patients in the United States are not receiving an effective treatment known as red blood cell exchange, despite its availability in a vast majority of hospitals. New research indicates that fewer than 3% of patients have undergone this procedure, even though 91% of surveyed healthcare providers report having access to the necessary technology.

The administration of red blood cell exchange therapy is hampered by several obstacles. Healthcare providers most frequently cited difficulties in coordinating between different medical departments, a shortage of donated blood, and a lack of familiarity with the procedure itself. Only a small fraction of providers reported no challenges in delivering this treatment.

Beyond provider-related issues, patient concerns about health insurance coverage for red blood cell exchange therapy are significant. Sickle cell disease affects over 100,000 people in the US, primarily people of color, with 90% being non-Hispanic Black or African American. Many of these patients face socioeconomic vulnerabilities, with approximately 80% relying on Medicaid.

Experts emphasize that expanding access requires growing the number of comprehensive sickle cell disease centers. These centers can consolidate essential expertise and services, offering coordinated care that is often unavailable in many communities. Furthermore, there's a recognized gap in provider knowledge regarding the treatment of sickle cell disease, necessitating increased awareness and training on national guidelines.